These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7846012)

  • 1. CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience.
    Satake K; Takeuchi T; Homma T; Ozaki H
    Pancreas; 1994 Nov; 9(6):703-6. PubMed ID: 7846012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
    Satake K; Takeuchi T
    Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.
    Kim JE; Lee KT; Lee JK; Paik SW; Rhee JC; Choi KW
    J Gastroenterol Hepatol; 2004 Feb; 19(2):182-6. PubMed ID: 14731128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
    Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
    World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
    O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF
    Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9.
    Forsmark CE; Lambiase L; Vogel SB
    Pancreas; 1994 Nov; 9(6):731-4. PubMed ID: 7846016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.
    Herreros-Villanueva M; Ruiz-Rebollo L; Montes M; Rodriguez-Lopez M; Francisco M; Cubiella J; Iyo E; Garabitos E; Martínez Moneo E; Martos M; de Madaria E; Martínez-Arránz I; García-Cougil M; Iglesias-Gómez A; Bujanda L
    Mol Biol Rep; 2020 Mar; 47(3):1583-1588. PubMed ID: 31915999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA19-9: the Italian experience.
    Gullo L
    Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer.
    Månsson C; Nilsson A; Urdzik J; Karlson BM
    Anticancer Res; 2019 Nov; 39(11):6193-6196. PubMed ID: 31704847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
    Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
    JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy.
    Ge L; Pan B; Song F; Ma J; Zeraatkar D; Zhou J; Tian J
    BMJ Open; 2017 Dec; 7(12):e018175. PubMed ID: 29282264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
    Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
    Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposed cut-off value of CA19-9 for detecting pancreatic cancer in patients with diabetes: a case-control study.
    Murakami M; Nagai Y; Tenjin A; Tanaka Y
    Endocr J; 2018 Jun; 65(6):639-643. PubMed ID: 29643268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
    Luo G; Fan Z; Cheng H; Jin K; Guo M; Lu Y; Yang C; Fan K; Huang Q; Long J; Liu L; Xu J; Lu R; Ni Q; Warshaw AL; Liu C; Yu X
    Pancreatology; 2018 Dec; 18(8):971-976. PubMed ID: 30131287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer.
    Chari ST; Klee GG; Miller LJ; Raimondo M; DiMagno EP
    Gastroenterology; 2001 Sep; 121(3):640-5. PubMed ID: 11522748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T; Zhang MG; Yu XJ; Liu L
    Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: a prospective study in multiinstitutions.
    Kuno N; Kurimoto K; Fukushima M; Hayakawa T; Shibata T; Suzuki T; Sakakibara A; Katada N; Nakano S; Takayama T
    Pancreas; 1994 Nov; 9(6):725-30. PubMed ID: 7531333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.